Claims for disease-modifying therapy by Alberta non-insured health benefits clients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Claims for disease-modifying therapy by Alberta non-insured health benefits clients ; volume:16 ; number:1 ; day:24 ; month:8 ; year:2016 ; pages:1-8 ; date:12.2016
BMC health services research ; 16, Heft 1 (24.8.2016), 1-8, 12.2016
- Creator
-
Barnabe, Cheryl
- Contributor
-
Healy, Bonnie
Portolesi, Andrew
Kaplan, Gilaad G.
Hemmelgarn, Brenda
Weaselhead, Charles
SpringerLink (Online service)
- DOI
-
10.1186/s12913-016-1685-y
- URN
-
urn:nbn:de:1111-2016092114538
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Barnabe, Cheryl
- Healy, Bonnie
- Portolesi, Andrew
- Kaplan, Gilaad G.
- Hemmelgarn, Brenda
- Weaselhead, Charles
- SpringerLink (Online service)
Other Objects (12)
Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Disease-modifying factors in hereditary angioedema: an RNA expression-based screening
Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Disease-modifying factors in hereditary angioedema: an RNA expression-based screening
Disease-modifying drug initiation patterns in commercially insured multiple sclerosis patients: a retrospective cohort study
Current Disease-Modifying Therapies in Multiple Sclerosis
Disease-modifying treatments in Alzheimer’s disease
Disease-modifying effects of metabolic perturbations in ALS/FTLD
Current experimental disease-modifying therapeutics for multiple system atrophy
Lithium as a disease-modifying agent for prion diseases
Jellyfish mucin may have potential disease-modifying effects on osteoarthritis
Disease-modifying effects of ranibizumab for central retinal vein occlusion
Disease‐modifying effects of ganglioside GM1 in Huntington's disease models
Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis